Current Management of Psoriasis

References

• Rea I N, Newhouse M L, Hail T. Skin disease in Lambeth. A community study of prevalence and use of medical care. Br j Prev Soc Med 1976; 30: 107
   PubMedGoogle Scholar
• Jobling R G. Psoriasis - a preliminary questionnaire study of sufferers' subjective experience. Clin Exp Dermatol 1976; 1: 233
   PubMed Web of Science ®Google Scholar
• Workshop of the Research Unit of the Royal College of Physicians of London, the Department of Dermatology, LIniversity of Glasgow, and the British Association of Dermatologists, Guidelines for the management of patients with psoriasis. BMJ 1991; 303: 829–35
   PubMed Web of Science ®Google Scholar
• Scottish Intercollegiate Guidelines Network, Clinical guidelines: criteria for appraisal for national use. Royal College of Physicians, Edinburgh 1995
   Google Scholar
• Ramsay B, O'Reagan M. A survey of the social and psychological effects of psoriasis. Br J Dermatol 1988; 118: 195–201
   PubMed Web of Science ®Google Scholar
• Finlay A Y, Coles E C. The effect of severe psoriasis on the quality of life of 369 patients. Br I Dermatol 1995; 132: 236–44
   PubMed Web of Science ®Google Scholar
• Finlay A Y, Kelly S E. Psoriasis - an index of disability. Clin Exp Dermatol 1987; 12: 8–11
   PubMed Web of Science ®Google Scholar
• Finlay A Y, Khan G K. Dermatology Life Quality index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210–16
   PubMed Web of Science ®Google Scholar
• Lewis-Jones M S, Finlay A Y. The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br I Dermatol 1995; 132: 942–9
   PubMed Web of Science ®Google Scholar
• Finlay A Y, Khan G K, Luscombe D K., et al. Validation of sickness impact profile and psoriasis disability index in psoriasis. Br j Dermatol 1990; 123: 751–6
   PubMed Web of Science ®Google Scholar
• Root S, Kent G, Al-Abadie M SK. The relationship between disease severity, disability and psychosocial distress in patients undergoing PUVA treatment for psoriasis. Dermatology 1994; 189: 234–7
   PubMed Web of Science ®Google Scholar
• Zug K A, Littenburg B, Baughman R D., et al. Assessing the preferences of patients with psoriasis. Arch Dermatol 1995; 131: 561–8
   PubMedGoogle Scholar
• Salek M S, Finlay A Y. Cyclosporin improves quality of life in psoriasis - does this matter?. Br I Dermatol 1993; 129(Suppl 42)32
   Google Scholar
• Kurwa H, Finlay A Y. Dermatology inpatient admission greatly improves life quality. Br I Dermatol 1995; 133: 575–8
   PubMed Web of Science ®Google Scholar
• Haisma H H, Kaptain A A. Social aspects of psoriasis, the Psoriasis Disability Index. 6th International Congress on Dermatology and Psychiatry. 20–22 April. Amsterdam 1995
   Google Scholar
• Larko O, Swanbeck G. Psoriasis treatment and a day-care centre; clinical aspects and an attempt at a cost-benefit analysis. Acta Derm Venereol 1982; 62: 413–18
   PubMed Web of Science ®Google Scholar
• Finlay A Y, Bryden J S. Integrated in-patient and out-patient dermatology management. Clin Exp Dermatol 1989; 14: 7–11
   PubMed Web of Science ®Google Scholar
• McCarthy M. An evaluation of a day-care service for psoriasis patients. M Soc Sci thesis, University College Dublin. 1978
   Google Scholar
• Sander H M, Morris L F, Phillips C M., et al. The annual cost of psoriasis. I Am Acad Dermatol 1993; 28: 422–5
   PubMed Web of Science ®Google Scholar
• Kreuger G G, Bergstresser P R, Lowe N J., et al. Psoriasis. J Am Acad Dermatol 1984; 11: 937–47
   PubMed Web of Science ®Google Scholar
• Cork M. Economic considerations in the treatment of psoriasis. Dermatol Pract Jan-Feb, 1993; 16–20
   Google Scholar
• Whittaker S, Berth-Jones J, Poyner T. Psoriasis: its diagnosis and choice of treatment. Prescriber 1992; 3: 31–68
   Google Scholar
• Allen B R. Treatment of psoriasis. Prescribers' journal 1993; 33: 183–90
   Google Scholar
• Ramsey B, O'Reagan M. A survey of the social and psychological effects of psoriasis. Br I Dermatol 1988; 118: 195–200
   PubMed Web of Science ®Google Scholar
• Young E. The external treatment of psoriasis. A controlled investigation of the effects of coal tar. Br J Dermatol 1970; 82: 510
   PubMed Web of Science ®Google Scholar
• Williams R EA, Tillman D, White S I., et al. Re-examining crude coal tar treatment for psoriasis. Br I Dermatol 1992; 126: 608–10
   PubMed Web of Science ®Google Scholar
• Kanzler M H, Gorsulowsky D C. Efficacy of topical 5% liquor carbonis detergens versus its emollient base in the treatment of psoriasis. Br I Dermatol 1993; 129: 310–13
   PubMed Web of Science ®Google Scholar
• Stern R S, Laird N. The carcinogenic risk of treatments for severe psoriasis. Cancer 1994; 73: 2759–64
   PubMed Web of Science ®Google Scholar
• van Schooten F J, Moonen E JC, Rhijnsburger E, et al. Dermal uptake of polycydic aromatic hydrocarbons after hairwash with coal-tar shampoo. Lancet 1995; 344: 1505–6
   Web of Science ®Google Scholar
• Ashton R E, Andre P, Lowe N, et al. Anthralin: historical and current perspectives.]. Am Acad Dermatol 1983; 9: 173–92
   PubMed Web of Science ®Google Scholar
• Paramsothy Y, Lawrence C M. Time course and intensity of anthralin inflammation on involved and uninvolved psoriatic skin. Br J Dermatol 1987; 116: 517–19
   PubMed Web of Science ®Google Scholar
• Vella Briffa D, Greaves M W, Warin A P., et al. Relapse rate and long term management of plaque psoriasis after treatment with photochemotherapy and dithranol. BMJ 1981; 282: 937–40
   PubMedGoogle Scholar
• Schaefer H, Farber E M, Goldberg L, et al. Limited application period for dithranol in psoriasis. Br I Dermatol 1980; 102: 571–3
   PubMed Web of Science ®Google Scholar
• Marsden J R, Coburn P R, Marks J M., et al. Measurement of the response of psoriasis to short term application of anthralin. Br I Dermatol 1988; 109: 209–18
   Google Scholar
• Ramsay B, Lawrence C M, Bruce M, Shuster S. The effect of triethanolamine application on anthralin-induced inflammation and therapeutic effect in psoriasis. J Am Acad Dermatol 1990; 23: 73–6
   PubMed Web of Science ®Google Scholar
• Paramsothy Y, Collins M, Lawrence C M. Effect of UV irradiation and coal tar bath on short contact anthralin therapy. Br I Dermatol 1988; 118: 783–9
   PubMed Web of Science ®Google Scholar
• Statham B V, Ryatt K S, Rowell N R. Short contact dithranol therapy - a comparison with the Ingram regimen. Br I Dermatol 1981; 110: 703–8
   Google Scholar
• Kragballe K. Treatment of psoriasis by the topical application of the novel cholecalciferol analogue calcipotriol (MS 903). Arch Dermatol 1989; 125: 1647–52
   PubMedGoogle Scholar
• Staberg B, Roed-Petersen J, Menne T. Efficacy of topical treatment in psoriasis with MC903, a new vitamin D analogue. Acta Derm Venereol 1989; 69: 147–50
   PubMed Web of Science ®Google Scholar
• Dubertret L, Wallachy D, Souteyrand P, et al. Efficacy and safety of calcipotriol (MC903) ointment in psoriasis vulgaris. A randomized, double-blind, right/left comparative, vehicle-controlled study. J Am Acad Dermatol 1992; 27: 983–8
   PubMed Web of Science ®Google Scholar
• Berth-Jones J, Chu A C, Dodd W AH, et al. A multicentre, parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis. Br J Dermatol 1992; 127: 266–71
   PubMed Web of Science ®Google Scholar
• Tham S N, Lun K C, Cheong W K. A comparative study of calcipotriol ointment and tar in chronic plaque psoriasis. Br J Dermatol 1994; 131: 673–7
   PubMed Web of Science ®Google Scholar
• Cunliffe W J, Berth-Jones J, Claudy A, et al. Comparative study of calcipotriol (MC903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. I Am Acad Dermatol 1993; 26: 736–43
   Web of Science ®Google Scholar
• Beradesca E, Vignoli E P, Farinelli N, et al. Non-invasive evaluation of topical calcipotriol versus clobetasol in the treatment of psoriasis. Acta Derm Venereol 1994; 74: 302–4
   PubMed Web of Science ®Google Scholar
• Ramsay C A, Berth-Jones J, Brundin G, et al. Long-term use of topical calcipotriol in chronic plaque psoriasis. Dermatology 1994; 189: 260–4
   PubMed Web of Science ®Google Scholar
• Poyner T, Hughes W, Dass B K., et al. Long term treatment of chronic plaque psoriasis with calcipotriol. J Dermatol Treat 1993; 4: 173–7
   Google Scholar
• Green C, Ganpule M, Harris D, et al. Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp. Br J Dermatol 1994; 130: 483–7
   PubMed Web of Science ®Google Scholar
• Klaber M R, Hutchinson P E, Pedvis-Leftick A, et al. Comparative effects of calcipotriol solution (50 mcg/ml) and betamethasone 17-valerate solution (1 mg/ml) in the treatment of scalp psoriasis. Br J Dermatol 1994; 131: 678–83
   PubMed Web of Science ®Google Scholar
• Darley C, Cunliffe W J, Ferguson I, et al. Safety and efficacy of calcipotriol ointment (Dovonex) in treating children with psoriasis vulgaris. Br I Dermatol 1993; 129: 129–33
   Google Scholar
• Mortensen L, Kraballe K, Wegmann E, et al. Treatment of psoriasis vulgaris with topical calcipotriol has no short-term effect on calcium or bone metabolism. A randomized, double-blind, placebo-controlled study. Acta Derm Venereol (Stockh) 1993; 73: 300–4
   PubMed Web of Science ®Google Scholar
• Gumowski-Sunek D, Rizzoli R, Saurat J II. Oral calcium tolerance test in extensive psoriasis treated with topical calcipotriol. Dermatology 1995; 190: 43–7
   PubMed Web of Science ®Google Scholar
• Berth-Jones J, Bourke J, Iqbal S J., et al. Urine calcium excretion during treatment of psoriasis with calcipotriol. Br J Dermatol 1993; 129: 411–14
   PubMed Web of Science ®Google Scholar
• Bourke J, Berth-Jones J, Hutchinson P E. High-dose topical calcipotriol in the treatment of extensive psoriasis vulgaris. Br I Dermatol 1993; 129: 74–6
   PubMed Web of Science ®Google Scholar
• Bourke J F, Berth-Jones J, Mumford R, et al. High dose topical calcipotriol consistently reduces serum parathyroid hormone levels. Clin Endocrinol 1994; 41: 295–7
   PubMed Web of Science ®Google Scholar
• Dwyer C, Chapman R S. Calcipotriol and hypercalcaemia. Lancet 1991; 338: 764–5
   PubMed Web of Science ®Google Scholar
• Russell S, Young M J. Hypercalcaemia during treatment of psoriasis with calcipotriol. Br I Dermatol 1994; 130: 795–6, (letter)
   PubMed Web of Science ®Google Scholar
• Hardman K A, Heath D A, Nelson H M. Hypercalcaemia associated with calcipotriol (Dovonex) treatment. BMI 1993; 306: 896
   PubMedGoogle Scholar
• Bourke J F, Berth-Jones J, Hutchinson P E. Hypercalcaemia with topical calcipotriol. BMI 1993; 306: 1344–5
   PubMedGoogle Scholar
• Yip J, Goodfield M. Contact dermatitis from MC903, a topical vitamin D3 analogue. Contact Dermatitis 1991; 25: 139–40
   PubMed Web of Science ®Google Scholar
• Bruynzeel D P, Hoi C W, Nieboer C. Allergic contact dermatitis to calcipotriol. Br] Dermatol 1992; 127: 66
   PubMed Web of Science ®Google Scholar
• de Groot A C. Contact allergy to calcipotriol. Contact Dermatitis 1994; 30: 242–3
   PubMed Web of Science ®Google Scholar
• Steinkjer B. Contact dermatitis from calcipotriol. Contact Dermatitis 1994; 31: 122
   PubMedGoogle Scholar
• Berth-Jones J, Bourke J F, Bailey K, et al. Generalised pustular psoriasis responds to topical calcipotriol. BMJ 1993; 305: 868–9
   Google Scholar
• Bourke H, Berth-Jones J, Hutchinson P E. Occlusion enhances the efficacy of topical calcipotriol in psoriasis vulgaris. Clin Exp Dermatol 1993; 18: 504–6
   PubMed Web of Science ®Google Scholar
• Nielsen P G. Calcipotriol or clobetasol propionate occluded with a hydrocolloid dressing for treatment of nummular psoriasis. Acta Derm Venereol 1993; 73: 394, (letter).
   PubMed Web of Science ®Google Scholar
• Bourke J F, Berth-Jones J, Hutchinson P E. High-dose topical calcipotriol in the treatment of extensive psoriasis vulgaris. Br] Dermatol 1993; 129: 74–6
   PubMed Web of Science ®Google Scholar
• Speight E L, Farr P M. Calcipotriol improves the response of psoriasis to PUVA. Br I Dermatol 1994; 130: 79–82
   PubMed Web of Science ®Google Scholar
• Frappaz A, Thivolet J. Calcipotriol in combination with PUVA: a randomized double-blind placebo study in severe psoriasis. Eur I Dermatol 1993; 3: 351–4
   Google Scholar
• Grossman R M, Thivolet J, Claudy A, et al. A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low dose cyclosporine: results of a multicenter placebo-controlled study. J Am Acad Dermatol 1994; 31: 68–74
   PubMed Web of Science ®Google Scholar
• Kerscher M, Volkenandt M, Plewig G, et al. Combination of phototherapy of psoriasis with calcipotriol and narrowband UVB. lancet 1993; 342: 923
   PubMed Web of Science ®Google Scholar
• Molin L, Liberton H, Weeldon H, et al. Efficacy and safety of calcipotriol ointment in combination with UVB therapy. Presented at the Third Congress of the European Academy of Dermatology and Venereology. Copenhagen 1993
   Google Scholar
• Cork M J, Stierle C, Davies L, et al. Cost effectiveness of psoriasis treatments. Presented at the Third Congress of the European Academy of Dermatology and Venereology. Copenhagen 1993
   Google Scholar
• Kato T, Rokugo M, Terui T, et al. Successful treatment of psoriasis with topical application of active vitamin D3 analogue, 1,24-dihydroxycholecalciferol. Br I Dermatol 1986; 115: 431–3
   PubMed Web of Science ®Google Scholar
• Baadsgaard O, Traulsen J, Roed-Petersen J, et al. Optimal concentration of tacalcitol in once-daily treatment of psoriasis. J Dermatol Treat 1995; 6: 145–50
   Web of Science ®Google Scholar
• Cornell R C, Stroughton R B. Correlation of vaso constriction assay and clinical activity in psoriasis. Arch Dermatol 1985; 121: 63
   PubMed Web of Science ®Google Scholar
• English J SC, Bunker C B, Ruthven K, et al. A double-blind comparison of the efficacy of betamethasone dipropionate cream twice daily versus once daily in the treatment of steroid sensitive dermatoses. Clin Exp Dermatol 1989; 14: 32–4
   PubMed Web of Science ®Google Scholar
• Baker H, Ryan T J. Generalised pustular psoriasis. A clinical and epidemiological study of 104 cases. Br j Dermatol 1968; 80: 771–5
   PubMed Web of Science ®Google Scholar
• Wilkinson J M. Hypersensitivity to topical corticosteroids. Clin Exp Dermatol 1994; 19: 1–11
   PubMed Web of Science ®Google Scholar
• Greaves M W, Hay R J. Topical corticosteroids. J Roy Coll Phys 1987; 21: 32–4
   PubMedGoogle Scholar
• Greaves M W, Weinstein G D. Treatment of psoriasis. N Engl J Med 1995; 332: 581
   PubMed Web of Science ®Google Scholar
• Dootson G, Norris P G, Gibson C J., et al. The practice of ultraviolet phototherapy in the United Kingdom. Br] Dermatol 1991; 131: 873–7
   Google Scholar
• van Weelden H, Baart de la Faille H, Young E, et al. A new development in UVB phototherapy of psoriasis. Br I Dermatol 1988; 119: 11–19
   PubMed Web of Science ®Google Scholar
• Green C, Ferguson J, Lakshmipathi T, et al. 311 UV phototherapy - an effective treatment for psoriasis. Br I Dermatol 1988; 119: 691–6
   PubMed Web of Science ®Google Scholar
• Larko O. Treatment of psoriasis with a new UVB-lamp. Acta Derm Venereol 1989; 69: 357–9
   PubMed Web of Science ®Google Scholar
• Storbeck K, Holzle E, Lehmann P, et al. A new narrow-spectrum UV-B lamp (Philips TL 01/100 W, 311 nm) compared with conventional UV-B phototherapy: efficacy in psoriasis. Z. Hautkr 1991; 66: 708–12
   Google Scholar
• Picot E, Meunier I, Picot-Debeze M C, et al. Treatment of psoriasis with a 311-UVB lamp. Br J Dermatol 1992; 127: 509–12
   PubMed Web of Science ®Google Scholar
• Sterenborg H JCM, van Weelden H, Leun van der J C. The dose-response relationship for tumorigenesis by UV radiation in the region 311–312 nm. J Photochem Photobiol 1988; 2: 179–94
   Web of Science ®Google Scholar
• Hansen Flindt H, McFadden N, Eeg-Larsen T, et al. Effect of a new narrow-band UV-B lamp on photocarcinogenesis in mice. Acta Derm Venereol 1991; 71: 245–8
   PubMed Web of Science ®Google Scholar
• Gibbs N K, Traynor N J, Campbell I, et al. Phototumorigenic potential of broad-band (280–340 nm) and narrow-band (311–313 nm) phototherapy sources in hairless mouse skin. Br I Dermatol 1992; 127: 420
   Google Scholar
• Wulf H C, Hansen A B, Bech-Thomsen N. Differences in narrow-band ultraviolet B and broad-spectrum ultra- violet photocarcinogenesis in lightly pigmented hair- less mice. Photoderm Photoimmunol Photomed 1994; 10: 192–7
   PubMed Web of Science ®Google Scholar
• Young A R. Carcinogenicity of UVB phototherapy assessed. Lancet 1995; 345: 1431–2
   Web of Science ®Google Scholar
• Slaper I T, Schothorst A A, Leunvan der J C. Risk evaluation of LIVB therapy for psoriasis: comparison of calculated risk for UVB therapy and observed risk in PUVA-treated patients. Photodermatology 1986; 3: 271–83
   PubMedGoogle Scholar
• Stern R S, Laird N. The carcinogenic risk of treatments for severe psoriasis. Cancer 1994; 73: 2759–64
   PubMed Web of Science ®Google Scholar
• Young E. The external treatment of psoriasis. A controlled investigation of the effects of coal tar. Br J Dermatol 1970; 82: 510
   PubMed Web of Science ®Google Scholar
• Karvonen A., Kokkonen E L, Ruotsalainen E. 311 nm LJVB lamps in the treatment of psoriasis with the Ingram regimen. Acta Derm Venereol 1989; 69: 82–5
   PubMed Web of Science ®Google Scholar
• Storbeck K, Holzle E, Schurer N. Narrow-band (311) versus conventional broad-band LIVB with and without dithranol in phototherapy for psoriasis. J Am Acad Dermatol 1993; 28: 227–31
   PubMed Web of Science ®Google Scholar
• Kerscher M, Volkenandt M, Plewig G, et al. Combination phototherapy of psoriasis with calcipotriol and narrowband UVB. Lancet 1993; 342: 923
   PubMed Web of Science ®Google Scholar
• Green C., Lakshmipathi T, Lohnson B E, et al. A comparison of the efficacy and relapse rates of narrow-band UVB (TL-01) monotherapy vs etretinate (re-TL-01) vs etretinate-PUVA (re-PUVA) in the treatment of psoriasis patients. Br I Dermatol 1992; 127: 5–9
   PubMed Web of Science ®Google Scholar
• Ortel B, Perl S, Kinaciyan T, et al. Comparison of narrowband (311 nm) UVB and broad-band LLVA after oral or bath-water 8-methoxypsoralen in the treatment of psoriasis. J Am Acad Dermatol 1993; 29: 736–40
   PubMed Web of Science ®Google Scholar
• Sakuntabhai A, Diffey B L, Farr P M. Response of psoriasis to psoralen-UVB photochemotherapy. Br Dermatol 1993; 128: 296–300
   PubMed Web of Science ®Google Scholar
• Morison W L. Phototherapy and photochemotherapy of skin disease, 2nd edn. Raven Press, New York 1991
   Google Scholar
• Leun van der C, van Weelden H. UVB phototherapy: principles, radiation sources, regimens. Current problems in dermatology, H Honigsmann, G Stingle. Karger, Basel 1986; vol 15: 39–51
   Google Scholar
• Speight E L, Farr P M. Calcipotriol improves the response of psoriasis to PLFVA. Br j Dermatol 1994; 130: 79–82
   PubMed Web of Science ®Google Scholar
• Lowe N J, Prystowsky J H, Bourget T, et al. Acitretin plus UVB therapy for psoriasis. J Am Acad Dermatol 1991; 24: 591–4
   PubMed Web of Science ®Google Scholar
• British Photodermatology Group. British Photodermatology Group Guidelines for PUVA. BMJ 1994; 130: 246–55
   Google Scholar
• Photochemotherapy in dermatology, E A Abel. lgaku Shoin, New York, Tokyo 1992
   Google Scholar
• Carabott F M, Hawk J LM. A modified dosage schedule for increased efficiency in PUVA treatment of psoriasis. Clin Exp Dermatol 1989; 14: 337–40
   PubMed Web of Science ®Google Scholar
• Green C, George S, Lakshmipathi T, et al. A trial of accelerated PUVA in psoriasis. Clin Exp Dermatol 1993; 18: 297–9
   PubMed Web of Science ®Google Scholar
• Moseley H, Jones S K. Clear ultraviolet blocking lenses for use by PUVA patients. Br J Dermatol 1990; 123: 775
   PubMed Web of Science ®Google Scholar
• George S A, Ferguson J. Liquid formulations of 8-methoxypsoralen (8-MOP) and 5-MOP: a prospective double-blind crossover assessment of acute non-phototoxic adverse effects. Photoderm Photoimmunol Photomed 1992; 9: 33–5
   PubMed Web of Science ®Google Scholar
• Lowe N, Weingarten D, Bourget T, et al. PUVA therapy for psoriasis: comparison of oral and bath-water delivery of 8-methoxypsoralen.]. Am Acad Dermatol 1986; 14: 754–60
   PubMed Web of Science ®Google Scholar
• Lindelof B, Sigurgeirsson B, Tegner E, et al. Comparison of the carcinogenic potential of trioxsalen bath PUVA and oral methoxsalen PUVA. Arch Dermatol 1992; 128: 1341–4
   PubMedGoogle Scholar
• Frappaz A, Thivolet J. Calcipotriol in combination with PUVA: a randomized double blind placebo study in severe psoriasis. Eur J Dermatol 1993; 3: 351–4
   Google Scholar
• Fritsch P, Honigsmann H. Combination phototherapy: a critical reappraisal. Curr Probl Dermatol 1986; 15: 238–53
   PubMedGoogle Scholar
• Ryan T J, Vickers H R, Salem S N., et al. The treatment of psoriasis with folic acid antagonists. Br I Dermatol 1964; 76: 555–64
   PubMed Web of Science ®Google Scholar
• Dahl M GC, Gregory M M, Scheuer P J. Methotrexate hepatotoxicity in psoriasis - comparison of different dosage regimens. BMJ 1972; 1: 654–66
   PubMed Web of Science ®Google Scholar
• Shapiro H A, Trowbridge I O, Lee J C, et al. Liver disease in psoriatics — an effect of methotrexate therapy?. Arch Dermatol 1974; 110: 547–51
   PubMedGoogle Scholar
• van de Kerkhof P CM, Hoefnagels W HL, van Haelst U IGM, et al. Methotrexate maintenance therapy and liver damage in psoriasis. Clin Exp Dermatol 1985; 10: 194–200
   PubMed Web of Science ®Google Scholar
• Boffa M I, Chalmers R JG, Haboubi N Y., et al. Sequential liver biopsies during long-term methotrexate treatment for psoriasis: a reappraisal. Br] Dermatol 1995; 133: 774–8
   PubMed Web of Science ®Google Scholar
• van Dooren-Greebe R J, Kuijpers A LA, Mulder J, et al. Methotrexate revisited: effects of long-term treatment in psoriasis. Br] Dermatol 1994; 130: 204–10
   PubMed Web of Science ®Google Scholar
• Shupack J L, Webster G F. Pancytopenia following low-dose oral methotrexate therapy for psoriasis. ]AMA 1988; 259: 3594–6
   PubMed Web of Science ®Google Scholar
• Evans W E, Christensen M L. Drug interactions with methotrexate. J Rheumatol 1985; 12: 15–20
   Web of Science ®Google Scholar
• Nyfors A. Methotrexate therapy of psoriasis. Dan Med Bull 1980; 27: 74–96
   PubMedGoogle Scholar
• Milunsky A, Graef F W, Gaynor M F, Jr. Methotrexate-induced congenital malformations. J Pediatr 1968; 72: 790–5
   PubMed Web of Science ®Google Scholar
• Powell H R, Ekert H. Methotrexate-induced congenital malformations. Med I Aust 1971; 2: 1076–7
   PubMed Web of Science ®Google Scholar
• Roenigk H H, Auerbach R, Maibach H I., et al. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol 1988; 19: 145–56
   PubMed Web of Science ®Google Scholar
• Perry W H. Methotrexate and teratogenesis. Arch Dermatol 1983; 119: 874
   PubMedGoogle Scholar
• Kroner T H, Tschumi A. Conception of normal child during chemotherapy of acute lymphoblastic leukaemia in the father. Br Med 1 1997; 1: 1322–3
   Google Scholar
• Melnyk J, Duffy D M, Sparkes R S. Human mitotic and meiotic chromosomal damage following in vivo exposure to methotrexate. Clin Genet 1971; 11: 28–31
   Google Scholar
• Krogh Jensen M, Nyfors A. Cytogenetic effect of methotrexate on human cells in vivo: comparison between results obtained by chromosome studies on bone-marrow cells and blood lymphocytes and by the micronucleus test. Mutat Res 1979; 64: 339–43
   PubMedGoogle Scholar
• Sussman A, Leonard J M. Psoriasis, methotrexate and oligospermia. Arch Dermatol 1980; 116: 215–17
   PubMed Web of Science ®Google Scholar
• Weinstein G D, Frost P. Methotrexate for psoriasis - a new therapeutic schedule. Arch Dermatol 1971; 103: 33–8
   PubMed Web of Science ®Google Scholar
• Zanolli M D, Sheretz E F, Hedberg A E. Methotrexate: anti-inflammatory or antiproliferative?. J Am Acad Dermatol 1990; 22: 523–4
   PubMed Web of Science ®Google Scholar
• Roenigk H H, Jr, Auerback R, Bergfeld W F., . A cooperative prospective study of the effects of psoriasis on liver biopsies. Psoriasis: Proceedings of the Second International Symposium., E M Farber, A Cox, et al. Yoke Medical Books, New York 1977; 234–8
   Google Scholar
• Weinstein G D, Roenigk H, Maibach H I., et al. Psoriasis-liver-methotrexate interactions. Arch Dermatol 1973; 108: 36–42
   PubMedGoogle Scholar
• Mitchell D O, Johnson R J, Testa H E., et al. Ultrasound and radionuclide scans - poor indicators of liver damage in patients treated with methotrexate. Clin Exp Dermatol 1987; 12: 243–4
   PubMed Web of Science ®Google Scholar
• Zachariae H, Sogaard H. Methotrexate-induced liver cirrhosis - a follow-up. Dermatologica 1987; 175: 178–82
   PubMedGoogle Scholar
• Lanse S B, Arnold G L, Gowans J DC, et al. Low incidence of hepatotoxicity associated with long-term low-dose, oral methotrexate in treatment of refractory psoriasis, psoriatic arthritis and rheumatoid arthritis: an acceptable risk/benefit ratio. Dig Dis Sci 1985; 30: 104–9
   PubMed Web of Science ®Google Scholar
• Watson R GP, Smallwood R A. Low dose methotrexate therapy and hepatotoxicity - the view of the hepatologist. Med I Am 1991; 155: 428–30
   Google Scholar
• Boffa M J, Smith A, Chalmers R G, et al. Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients. Br I Dermatol 1996; 135: 538–44
   PubMed Web of Science ®Google Scholar
• Duhra P. Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. J Am Acad Dermatol 1993; 28: 466–9
   PubMed Web of Science ®Google Scholar
• Morgan S L, Alarcon G S, Krumdieck C L. Folic acid supplementation during methotrexate therapy: it makes sense. J Rheumatol 1993; 20: 929–30
   PubMed Web of Science ®Google Scholar
• Dodd H E, Kirby J DT, Munro D D. Megaloblastic anaemia in psoriatic patients treated with methotrexate. Br Dermatol 1985; 112: 630–1
   PubMed Web of Science ®Google Scholar
• Brindley C J. Overview of recent pharmacokinetic studies with acitretin (Ro 10–1670-etretin). Dermatologica 1989; 178: 79–87
   PubMedGoogle Scholar
• Vahlquist A, Rollman O, Pihl-Lundin I. Tissue distribution of aromatic retinoid (etretinate) in three autopsy cases: drug accumulation in adrenals and fat. Acta Derm Venereol 1986; 66: 431–4
   PubMed Web of Science ®Google Scholar
• Paravicini U, Camenzind M, Gower M, . Multiple dose pharmacokinetics of Ro 10–1670, the main metabolite of etretinate (Tigason). Retinoids: new trends in research and therapy., Saurat, et al. S Karger, Basel 1985; 289–92
   Google Scholar
• Larsen F G, Jakobsen P, Larsen C G., et al. Pharmacokinetics of etretin and etretinate during long term treatment of psoriasis patients. Pharmacol Toxicol 1988; 62: 159–65
   PubMedGoogle Scholar
• Rollman O, Vahlquist A. Retinoid concentrations in skin, serum and adipose tissue of patients treated with etretinate. Br J Dermatol 1983; 109: 439–47
   PubMed Web of Science ®Google Scholar
• Goldfarb M T, Ellis C N, Gupta A K., et al. Acitretin improves psoriasis in a dose dependent fashion. J Am Acad Dermatol 1988; 18: 655–62
   PubMed Web of Science ®Google Scholar
• Berbis P, Geiger J M, Vaisse C, et al. Benefit of progressively increasing doses during the initial treatment with acitretin in psoriasis. Dermatologica 1989; 178: 88–92
   PubMedGoogle Scholar
• Kingston T P, Matt L H, Lowe N J. Etretin therapy for severe psoriasis. Arch Dermatol 1987; 123: 55–8
   PubMedGoogle Scholar
• Gollnick H, Bauer R, Brindley C, et al. Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study. J Am Acad Dermatol 1988; 19: 458–69
   PubMed Web of Science ®Google Scholar
• Kragballe K, Jansen C T, Geiger J M., et al. A double blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Acta Derm Venereol (Stockh) 1989; 69: 35–40
   PubMed Web of Science ®Google Scholar
• Saurat J H, Geiger J M, Amblard P, et al. Randomized double-blind multicenter study comparing acitretin PUVA, etretinate PUVA and placebo PUVA in the treatment of severe psoriasis. Dermatologica 1988; 177: 218–24
   PubMedGoogle Scholar
• Mills C, Marks R. Adverse reactions to oral retinoids - an update. Drug Safety 1993; 9: 280–90
   PubMed Web of Science ®Google Scholar
• Geiger J M, Saurat J H. Acitretin and etretinate: how and when they should be used. Dermatol Clin 1993; 11: 1
   PubMed Web of Science ®Google Scholar
• Geiger J M, Baudin M, Saurat J H. Teratogenic risk with etretinate and acitretin treatment. Dermatology 1994; 189: 109–16
   PubMed Web of Science ®Google Scholar
• Roenigk H R. Liver toxicity in retinoid therapy. J Am Acad Dermatol 1988; 19: 199–208
   PubMed Web of Science ®Google Scholar
• Mills C M, Marks R. Etretinate hepatitis. J Dermatol Treat 1994; 5: 145–6
   Google Scholar
• Kilcoyne R F. Effects of retinoids in bone. J Am Acad Dermatol 1988; 19: 212–16
   PubMed Web of Science ®Google Scholar
• Ellis C N, Gorsulowsky D C, Hamilton T A., et al. Cyclosporin improves psoriasis in a double-blind study. JAMA 1986; 256: 3110–16
   PubMed Web of Science ®Google Scholar
• Mueller W, Herrmann B. Cyclosporin A for psoriasis. N Engl] Med 1979; 301: 555
   PubMed Web of Science ®Google Scholar
• van Joost T, Bos I D, Heule F, et al. Low-dose cyclosporin A in severe psoriasis. A double-blind study. Br J Dermatol 1988; 118: 183–90
   PubMed Web of Science ®Google Scholar
• Ellis C N, Fradin M S, Messana M, et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl] Med 1991; 324: 277–84
   PubMed Web of Science ®Google Scholar
• Amerio P, Gravante M, Andreassi M, et al. Cyclical immunotherapy in patients with psoriasis. Acta Derm Venereol Suppl (Stockh) 1994; 186: 101–2
   PubMedGoogle Scholar
• Levell N J, Shuster S, Munro C S., et al. Remission of ordinary psoriasis following a short clearance course of cyclosporin. Acta Derm Venereol 1995; 75: 65–9
   PubMed Web of Science ®Google Scholar
• Harper I I, Keat A C, Staughton R C. Cyclosporin for psoriasis. Lancet 1984; 2: 981–2
   PubMed Web of Science ®Google Scholar
• van Hooff J P, Leunissen K M, Staak van der W. Cyclosporin and psoriasis. Lancet 1985; 1: 335
   PubMed Web of Science ®Google Scholar
• Fry L, Griffiths C E, Powles A V., et al. Long-term cyclosporine in the management of psoriasis. Transplant Proc 1988; 20(Suppl 4)23–5
   PubMedGoogle Scholar
• Higgins E, Munro C, Marks, et al. Relapse rates in moderately severe chronic psoriasis treated with cyclosporin A. Br] Dermatol 1989; 121: 71–4
   PubMed Web of Science ®Google Scholar
• Heule Bousema F. M, Laeijendecker T. R, et al. Three long-term regimens with cyclosporin for psoriasis vulgaris. Acta Derm Venereol Suppl (Stockh) 1989; 146: 171–5
   PubMedGoogle Scholar
• Cimitan A, Fantini F, Giannetti A. Clinical trial with cyclosporin A. Acta Derm Venereol Suppl (Stockh) 1989; 146: 159–62
   PubMedGoogle Scholar
• Timonen P, Friend D, Abeywickrama K, et al. Efficacy of low-dose cyclosporin A in psoriasis: results of dose-finding studies. Br] Dermatol 1990; 122(Suppl 36)33–9
   PubMedGoogle Scholar
• Korstanje M J, van de Staak W. Long-term treatment of psoriasis with cyclosporin A - side-effects, minimal effective dose and cyclosporin blood levels. Clin Exp Dermatol 1991; 16: 8–10
   PubMed Web of Science ®Google Scholar
• Christophers E, Mrowietz U, Henneicke H H., et al. Cyclosporine in psoriasis: a multicenter dose-finding study in severe plaque psoriasis. The German Multicenter Study. J Am Acad Dermatol 1992; 26: 86–90
   PubMed Web of Science ®Google Scholar
• Anonymous. Short- and long-term considerations concerning the management of plaque psoriasis with low-dose cyclosporin. Studio ltaliano Multicentrico nella Psoriasi (SIMPSO). Dermatology 1993; 187(Suppl 1)19–29
   Google Scholar
• Anonymous. Cyclosporin versus etretinate: Italian multicenter comparative trial in severe plaque-form psoriasis. Italian Multicenter Study Group on Cyclosporin in Psoriasis. Dermatology 1993; 187(Suppl 1)8–18
   PubMedGoogle Scholar
• Finzi A F, Mozzanica N, Cattaneo A, et al. Effectiveness of cyclosporine treatment in severe psoriasis: a clinical and immunologic study. J Am Acad Dermatol 1989; 21: 91–7
   PubMed Web of Science ®Google Scholar
• Powles A V, Baker B S, Valdimarsson H, et al. Four years of experience with cyclosporin A for psoriasis. Br] Dermatol 1990; 122(Suppl 36)13–19
   PubMedGoogle Scholar
• Anonymous. Management of erythrodermic psoriasis with low-dose cyclosporin. Studio ltaliano Multicentrico nella Psoriasi (SIMPSO). Dermatology 1993; 187(Suppl 1)30–7
   Google Scholar
• Meinardi M M, Westerhof W, Bos I D. Generalized pustular psoriasis (von Zumbusch) responding to cyclosporin A. Br] Dermatol 1987; 116: 269–70
   PubMed Web of Science ®Google Scholar
• Reitamo S, Puska P, Lassus A. Cyclosporin in the treatment of palmo-plantar pustulosis. Br I Dermatol 1989; 120: 857
   PubMed Web of Science ®Google Scholar
• Gupta A K, Ellis C N, Nickoloff B, et al. Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. Arch Dermatol 1990; 126: 339–50
   PubMedGoogle Scholar
• Mahrle G, Schulze H I, Farber L, et al. Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol 1995; 32: 78–88
   PubMed Web of Science ®Google Scholar
• Harper J I, Zemelman V, Keat A C., et al. Cyclosporine for psoriasis', beneficial effect in refractory skin and joint disease. Transplant Proc 1988; 20(Suppl 4)63–7
   PubMedGoogle Scholar
• Steinsson K, Jonsdottir I, Valdimarsson H. Cyclosporin A in psoriatic arthritis: an open study. Ann Rheum Dis 1990; 49: 603–6
   PubMed Web of Science ®Google Scholar
• Bianchi L, Gatti S, Nini G. Bullous pemphigoid and severe erythrodermic psoriasis: combined low-dose treatment with cyclosporine and systemic steroids. J Am Acad Dermatol 1992; 27: 278
   PubMed Web of Science ®Google Scholar
• Feutren G, Abeywickrama K, Friend D, et al. Renal function and blood pressure in psoriatic patients treated with cyclosporin A. Br J Dermatol 1990; 122(Suppl 36)57–69
   PubMedGoogle Scholar
• De Rie M A, Meinardi M M, Bos J D. Analysis of side-effects of medium- and low-dose cyclosporin maintenance therapy in psoriasis. Br 1 Dermatol 1990; 123: 347–53
   PubMed Web of Science ®Google Scholar
• Powles A V, Carmichael D, Hulme B, et al. Renal function after long-term low-dose cyclosporin for psoriasis. Br J Dermatol 1990; 122: 665–9
   PubMed Web of Science ®Google Scholar
• Berth-Jones I, Sowden J M, Feehally I, et al. Treatment of severe refractory atopic dermatitis with cyclosporin. Lancet 1991; 338: 643
   PubMedGoogle Scholar
• Brown A L, Wilkinson R, Thomas T H., et al. The effect of short-term low-dose cyclosporin on renal function and blood pressure in patients with psoriasis. Br J Dermatol 1993; 128: 550–5
   PubMed Web of Science ®Google Scholar
• Korstanje M J, Bilo H J, Stoof T J. Sustained renal function loss in psoriasis patients after withdrawal of low-dose cyclosporin therapy. Br I Dermatol 1992; 127: 501–4
   PubMed Web of Science ®Google Scholar
• Zachariae H, Hansen H E, Kragballe K, et al. Morphologic renal changes during cyclosporine treatment of psoriasis. Studies on pretreatment and posttreatment kidney biopsy specimens. J Am Acad Dermatol 1992; 26: 415–19
   PubMed Web of Science ®Google Scholar
• Sander H M, Morris L F, Phillips C M., et al. The annual cost of psoriasis. J Am Acad Dermatol 1993; 28: 422–5
   PubMed Web of Science ®Google Scholar
• Grossman R M, Thivolet J, Claudy A, et al. A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicentre placebo-controlled study. J Am Acad Dermatol 1994; 31: 68–74
   PubMed Web of Science ®Google Scholar
• Yarbro J W. Hydroxyurea in the treatment of refactory psoriasis. Lancet 1969; 2: 846–7
   PubMed Web of Science ®Google Scholar
• Yarbro J W, Leavell U W. Hydroxyurea: a new agent for the management of refractory psoriasis. J Ky Med Assoc 1969; 67: 899–901
   PubMedGoogle Scholar
• Leavell U W, Yarbro J W. Hydroxyurea. A new treatment for psoriasis. Arch Dermatol 1970; 102: 144–50
   PubMedGoogle Scholar
• Rosten M. Hydroxyurea: a new antimetabolite in the treatment of psoriasis. Br J Dermatol 1971; 85: 177–81
   PubMed Web of Science ®Google Scholar
• Hunter G A, Simmons I J, Thomas B M. A clinical trial of hydroxyurea for psoriasis. Australas] Dermatol 1972; 13: 93–9
   PubMedGoogle Scholar
• Moschella S L, Greenwald M A. Psoriasis with hydroxyurea. An 18-month study of 60 patients. Arch Dermatol 1973; 107: 363–8
   PubMed Web of Science ®Google Scholar
• Leavell U W, Mersack I P, Smith C. Survey of the treatment of psoriasis with hydroxyurea. Arch Dermatol 1973; 107: 467
   PubMedGoogle Scholar
• Layton A M, Sheehan-Dare R A, Goodfield M J., et al. Hydroxyurea in the management of therapy resistant psoriasis. Br J Dermatol 1989; 121: 647–53
   PubMed Web of Science ®Google Scholar
• Stein K M, Shelley W B, Weinberg R A. Hydroxyurea in the treatment of pustular psoriasis. Br] Dermatol 1971; 85: 81–5
   PubMed Web of Science ®Google Scholar
• Lingren S, Groth O. Generalised pustular psoriasis. A report on thirteen patients. Acta Derm Venereol 1976; 56: 139–47
   PubMed Web of Science ®Google Scholar
• Sauer G C. Combined methotrexate and hydroxyurea therapy for psoriasis. Arch Dermatol 1973; 107: 369–70
   PubMedGoogle Scholar
• Dahl M G, Comaish J S. Long-term effects of hydroxyurea in psoriasis. BMJ 1972; 1: 585–8
   PubMedGoogle Scholar
• Touraine R, Revuz J, Tulliez M. Psoriasis and hydroxyurea. Br] Dermatol 1972; 86: 102
   PubMed Web of Science ®Google Scholar
• Bauman L, Shulruff S, Hasegawa G R., et al. Fever caused by hydroxyurea. Arch Intern Med 1981; 141: 260–1
   PubMed Web of Science ®Google Scholar
• Kennedy B J, Smith L R, Goltz R W. Skin changes secondary to hydroxyurea therapy. Arch Dermatol 1975; 111: 183–7
   PubMed Web of Science ®Google Scholar
• Sander H M, Morris L F, Phillips C M., et al. The annual cost of psoriasis. J Am Acad Dermatol 1993; 28: 422–5
   PubMed Web of Science ®Google Scholar
• Gratton C EH. Evidence of an association between bullous pemphigoid and psoriasis. Br 1 Dermatol 1985; 113: 281–3
   PubMed Web of Science ®Google Scholar
• Hacker S M, Ramos-Caro F A, Ford M J., et al. Azathioprine: a forgotten alternative for treatment of severe psoriasis. Int I Dermatol 1992; 31: 873–4
   PubMed Web of Science ®Google Scholar
• du Vivier A, Munro D D, Verbov I. Treatment of psoriasis with azathioprine. BM 1974; 1(897)49–51
   PubMedGoogle Scholar
• Munro D D. Azathioprine in psoriasis. Proc Roy Soc Med 1973; 66: 747–8
   PubMedGoogle Scholar
• Mezzadra G, Randazzo S D, Mirone A. Esperienze terapeutiche con azathioprine nella psoriasi. G Ital Dermatol - Minerva Dermatol 1972; 47: 72–6
   PubMedGoogle Scholar
• Greaves M W, Dawber R. Azathioprine in psoriasis. BM) 1970; 2: 237–8
   PubMedGoogle Scholar
• Hewitt J, Escande I P, Leibowitch M, et al. Trial therapy of psoriasis with azathioprine. Bull Soc Fr Dermatol Syphiligr 1970; 77: 392–6
   PubMedGoogle Scholar
• Pinals R S. Azathioprine in the treatment of chronic polyarthitis: long term results and adverse effects in 25 patients. Rheumatol 1976; 3: 140–4
   Web of Science ®Google Scholar
• Clayton R. Azathioprine in psoriasis. BMJ 1974; 2: 443
   PubMedGoogle Scholar
• Dodd H J, Tatnall F M, Sarkany I. Fast atrial fibrillation induced by treatment of psoriasis with azathioprine. BM] 1985; 291: 706
   PubMed Web of Science ®Google Scholar
• Lawson D H, Lovatt G E, Gurton C S., et al. Adverse effects of azathioprine. Adverse Drug React Acute Poisoning Rev 1984; 3: 161–71
   PubMedGoogle Scholar
• Anstey A, Lennard L, Mayou S C., et al. Pancytopenia related to azathioprine - an enzyme deficiency caused by a common genetic polymorphism: a review. J Roy Soc Med 1992; 85: 752–6
   PubMed Web of Science ®Google Scholar
• McHenry P M, Allan J G, Rodger R S., et al. Nephrotoxicity due to azathioprine. Br I Dermatol 1993; 128: 106
   PubMed Web of Science ®Google Scholar
• Jones J J, Ashworth. Azathioprine-induced shock in dermatology patients. J Am Acad Dermatol 1993; 29: 795–6
   PubMed Web of Science ®Google Scholar
• Kinlen L J, Shiel A GR, Peto J, et al. Collaborative United Kingdom-Australian study of cancer in patients treated with immunosuppressive drugs. BM] 1979; 2: 1461–6
   PubMed Web of Science ®Google Scholar
• Connell W R, Kamm M A, Dickson M, et al. Long-term neoplasia risk after treatment in inflammatory bowel disease. Lancet 1994; 343: 1249–52
   PubMed Web of Science ®Google Scholar
• Armato M P, Pracucci G, Ponziani G, et al. Long term safety of azathioprine therapy in multiple sclerosis. Neurology 1993; 43: 831–3
   PubMedGoogle Scholar
• Champion R H. Treatment of psoriasis. BMJ 1966; 2: 993–5
   PubMedGoogle Scholar
• Baker H, Ryan T J. Generalised pustular psoriasis. Br I Dermatol 1968; 80: 771–93
   PubMed Web of Science ®Google Scholar
• Camp R DR. Psoriasis. Textbook of dermatology, 5th edn, A J Rook, D S Wilkinson, F JG Ebling, et al. Blackwell Scientific, Oxford 1992; 1391–456
   Google Scholar
• Baker H. Corticosteroids and pustular psoriasis. Br J Dermatol 1976; 94(Suppl 12)83–8
   PubMedGoogle Scholar
• Ryan T J, Baker H. Systemic corticosteroids and folic antagonists in the treatment of generalised pustular psoriasis. Br] Dermatol 1969; 81: 134–45
   PubMed Web of Science ®Google Scholar
• Lindgren S, Groth O. Generalized pustular psoriasis. A report on thirteen patients. Acta Derm Venereol 1976; 56: 139–47
   PubMed Web of Science ®Google Scholar